Guangzhou Mingxun Biotechnology
The unique tetraploid compensation technology scheme can directly prepare complete mouse individuals from mouse embryonic stem cells, bypassing the time-consuming breeding steps of conventional technology, the preparation time can be shortened to within 2-4 months, and the success rate is high.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
* | CNY10.0m | Seed | |
| Total Funding | 000k | ||
Related Content
Mingceler operates in the biotechnology sector, focusing on providing advanced solutions for in vitro fertilization (IVF) quality control. The company serves fertility clinics and research institutions, offering specialized assays and genome editing strategies to enhance the success rates of IVF procedures. Mingceler’s core product includes mouse embryo assays, which are used to ensure the quality and viability of embryos before implantation. Additionally, the company leverages CRISPR Cas9 technology to deliver precise genome editing solutions, further improving the outcomes of IVF treatments.
The business model is primarily B2B, generating revenue through the sale of its proprietary assays and genome editing services. By addressing the critical need for quality control in IVF, Mingceler positions itself as a key player in the reproductive biotechnology market.
Keywords: IVF quality control, mouse embryo assay, CRISPR Cas9, genome editing, fertility clinics, reproductive biotechnology, embryo viability, B2B, biotechnology solutions, IVF success rates.